Cancer patients frequently develop skeletal metastases that significantly impact quality of life. Since bone metastases remain incurable, a clearer understanding of molecular mechanisms regulating skeletal metastases is required to develop new therapeutics that block establishment of tumors in bone. While many studies have suggested that the microenvironment contributes to bone metastases, the factors mediating tumors to progress from a quiescent to a bone-destructive state remain unclear. In this study, we hypothesized that the "soil" of the bone microenvironment, specifically the rigid mineralized extracellular matrix, stimulates the transition of the tumor cells to a bone-destructive phenotype. To test this hypothesis, we synthesized 2D polyurethane (PUR) films with elastic moduli ranging from the basement membrane (70 MPa) to cortical bone (3800 MPa) and measured expression of genes associated with mechanotransduction and bone metastases. We found that expression of Integrin b3 (Ib3), as well as tumor-produced factors associated with bone destruction (Gli2 and parathyroid hormone related protein (PTHrP)), significantly increased with matrix rigidity, and that blocking Ib3 reduced Gli2 and PTHrP expression. To identify the mechanism by which Ib3 regulates Gli2 and PTHrP (both are also known to be regulated by TGF-b), we performed F€ orster resonance energy transfer (FRET) and immunoprecipitation, which indicated that Ib3 co-localized with TGF-b Receptor Type II (TGF-b RII) on rigid but not compliant films. Finally, transplantation of tumor cells expressing Ib3 shRNA into the tibiae of athymic nude mice significantly reduced PTHrP and Gli2 expression, as well as bone destruction, suggesting a crucial role for tumor-produced Ib3 in disease progression. This study demonstrates that the rigid mineralized bone matrix can alter gene expression and bone destruction in an Ib3/TGF-b-dependent manner, and suggests that Ib3 inhibitors are a potential therapeutic approach for blocking tumor transition to a bone destructive phenotype.
Introduction
Many of the most common tumors metastasize to bone, including breast, lung, and prostate cancer. It is estimated that 70% of breast cancer and 90% of prostate cancer patients with metastatic disease will develop bone metastases [1] . These metastases often develop years after the primary disease has been removed and are a major cause of morbidity and mortality [2, 3] . The primary clinical treatments for bone metastases focus on inhibiting bone resorption. While resorption inhibitors, like bisphosphonates, extend time to the first skeletal-related event, they neither directly inhibit tumor burden nor significantly extend survival when given after the diagnosis of a bone metastasis [4] . Thus, newer approaches are needed to improve patient outcomes [4] , which require a mechanistic understanding of why some tumors establish in bone.
Recent evidence indicates that metastasis to bone and other organs can be predicted from the genes expressed by the primary tumor [5e9], but the mechanisms by which gene expression patterns and metastatic traits specific to bone transpire in tumor cells remains an unanswered question. A seminal study has shown that the breast tumor stroma contributes to the selection of invasive triple-negative (TN) breast cancer cells that are conditioned for metastasis to bone [10] . While this "metastasis seed pre-selection" mechanism affirms the role of the breast stroma to bestow an advantage for tumor cells to establish in bone, the factors mediating progression of the tumor cells from the pre-osteolytic to the osteolytic phase are unknown [11] . When metastatic tumor cells establish in bone, they secrete parathyroid hormone-related protein (PTHrP), interleukin 6 and 8, and/or other factors that induce osteoblast expression of Receptor Activator of NF-kb Ligand (RANKL) [12, 13] . The consequent stimulation of osteoclastmediated bone resorption results in release of TGF-b and other growth factors from the extracellular matrix that continues to drive the expression of PTHrP by the tumor cells [14, 15] , which is regulated by the transcription factor Gli2 [14] . However, it is still unclear how bone microenvironmental effects on TGF-b signaling regulate gene expression in tumor cells or why tumors recur in the bone many years after the primary tumor has been removed. More clearly understanding the events that induce progression from a pre-osteolytic to an osteolytic phenotype may allow clinicians to better predict which tumors may form bone metastases and may allow for improved treatments.
The mineralized extracellular matrix, which has an elastic modulus ranging from 10 3 e 10 6 kPa [16] differentiates bone from other tissues. Expression of Gli2 and PTHrP by tumor cells in vitro correlates with bone-like matrix rigidity, which has been attributed to cross-talk between TGF-b and Rho-associated kinase (ROCK)
[16e18], a factor regulating cell contractility [19] . Integrinmediated cell-matrix interactions generate an adhesion moleculeintegrin-actomyosin complex that can be shifted between inactive and signaling states by activation of myosin II or matrix rigidity [20] . However, recent studies suggest that rigidity-mediated changes in gene expression are driven by uniform displacements (100e150 nm) of the matrix [21e23] . Considering that cells cannot generate displacements >100 nm on substrates more rigid than 10e100 kPa [21] , 100 kPa has been proposed as the upper limit at which cells enter a state of isometric contraction and cannot respond to further changes in rigidity [24] . Thus, the previously reported correlations of tumor cell proliferation [25] , invasiveness [25] , and expression of bone metastatic genes [16] with rigidity over ranges comparable to mineralized bone (10 3 e10 6 kPa) cannot be explained by uniform displacements of the matrix. These observations raise questions regarding the mechanisms by which matrix rigidity regulates tumor cell gene expression in the mineralized bone microenvironment. We hypothesized that when tumor cells become established in bone, the "soil" of the bone microenvironment, which is > 10 3 more rigid than the primary site, stimulates their transition from the pre-osteolytic to the osteolytic phase. We further postulated that the transition to the osteolytic phenotype on substrates with bone-like rigidity is mediated by integrins, but not by uniform displacements of the matrix as reported previously [21e23] due to its high rigidity (>100 kPa). TGF-b Receptor type II (TGF-b RII) interacts physically with b3 integrin sub-unit (Ib3) to enhance TGF-b-mediated stimulation of MAP-kinases (MAPKs) during epithelial-mesenchymal transition (EMT) of mammary epithelial cells (MECs) [26] . However, the role of matrix rigidity in promoting interactions between these receptors has not been explored. We used a 2D polyurethane (PUR) film monoculture system to design matrices with rigidities ranging from that of the basement membrane to cortical bone, which is far more rigid than previous studies have examined. In vitro studies demonstrated that Ib3 expression correlated with bone-like rigidity, which led to colocalization of Ib3 with TGF-b RII and increased expression of PTHrP. Inhibition of tumor-produced Ib3 by molecular and genetic interference decreased expression of PTHrP and Gli2 in vitro and reduced bone destruction in vivo. These observations provide evidence for a previously unexplored mechanism by which crosstalk between solid-state and soluble factor signaling switches on osteolytic signaling in tumor cells.
Materials and methods

Materials
Lysine diisocyanate (LDI) was purchased from Kyowa Hakko (New York, NY). Glycerol, stannous octoate, and ε-caprolactone were purchased from SigmaeAldrich (St. Louis, MO). Glycolide and DL-lactide were supplied by Polysciences (Warrington, PA). COSCAT 83 bismuth catalyst was acquired from Vertullus (Hopewell, VA). Fibronectin (Fn) was purchased from Life Technologies (Grand Island, NY). The human breast cancer cell line, MDA-MB-231 was originally purchased from ATCC and a bone-tropic clone was generated by our laboratory [27] . The human squamous lung cancer cell line, RWGT2, was derived as previously described [28] . The human adenocarcinoma cell line, PC3 was purchased from ATCC. Dulbecco's Modification of Eagle's Medium (DMEM), Minimum
Essential Medium a (a-MEM), and RMPI media were supplied by Mediatech (Manassas, VA). All media was supplemented with 10% Fetal Bovine Serum (Atlas, Fort Collins, CO) and 1% Penicillin and Streptomycin (Mediatech).
Synthesis of 2D substrates for cell culture experiments
2D films with varying rigidity were prepared for the cell culture experiments. The parameter typically used to quantify the rigidity of tissues and synthetic matrices is the elastic modulus, which is defined by the initial slope of the stress (s) versus strain (ε) curve. Poly(ester urethane) (PUR) substrates were synthesized and characterized as described previously [29] . Briefly, an appropriate amount of poly(ε-caprolactone-co-glycolide) triol (Mn ¼ 300, 600, 720 or 3000 g/mol) was mixed with an LDI-PEG prepolymer and COSCAT 83 catalyst (Vertellus) for 20s in a Hauschild SpeedMixerTM DAC 150 FVZ-K vortex mixer (FlackTek, Inc, Landrum, SC) (Fig. 1A) . The targeted index (ratio of NCO to OH equivalents times 100) was 105. The resultant mixture was poured into the wells of a tissue culture plate and allowed to cure for 24 h at 60 C.
Measurement of elastic modulus by nanoindentation
Nanoindentation measurements were performed as shown in Fig. 1BeE to determine the Young's modulus of the substrate (E s ) by the method of Oliver and Pharr [30] . The reduced modulus E r was calculated from load-displacement data acquired in the nanoindentation measurements:
where A is the indenter contact area and the stiffness S is calculated from the initial slope of the unloading curve. The Young's modulus of the substrate E s is related to the reduced modulus, the Young's modulus of the diamond indenter (E i ¼ 1141 GPa) and the Poisson ratios of the indentor (n i ¼ 0.07) and the PUR substrate (n s ¼ 0.5):
The Young's moduli of the PUR films (E s ) used in this study as obtained by nanoindentation are listed in Fig. 1E .
Fibronectin adsorption
To facilitate cell adhesion and ensure that the surface chemistry was constant for all substrates tested, fibronectin (Fn) was adsorbed to the surface of the substrates by incubation in a solution of Fn in PBS (0.5e50 4 mg/mL) at 4 C overnight. Coated substrates were incubated in a solution of Fn antibody (1:1000) followed by incubation with a secondary HRP-conjugated antibody to measure the surface concentration of Fn. The relative amount of adsorbed antibody was then quantified by reaction with 2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) and subsequent optical density reading at 405 nm. With the exception of the Fn dose response experiment (Fig. 2E) , PUR scaffolds were treated with 4.0 mg cm À3 Fn. overexpressing plasmid (Obtained from Addgene from Dr. Timothy Springer, Boston Children's Hospital [31] ) using lipofectamine and plus reagent (Life Technologies) per manufacturer's instructions. To inhibit Ib3, MDA-MB-231 cells were stably transfected with a targeted shRNA (Santa Cruz) or a control plasmid (Santa Cruz) using an shRNA transfection reagent (Santa Cruz) per manufacturer's instructions. All cells were cultured at 37 C with 5% CO 2 .
Drug treatments
For Ib3 signaling experiments, cells were treated with the avb3 antibody LM609 (EMD Millipore) at 10ug/mL or control antibody 12CA5 (Vanderbilt Antibody Core), the RGD-mimicking peptide Cilengitide (Selleckchem) at 10 mM, the actin-myosin inhibitor Blebbistatin (Sigma) at 50 mM, and the src stimulating peptide Bombesin (Sigma) at 20 nM or DMSO control for 24 h under normal culture conditions. For TGF-b signaling experiments, cells were treated with 5 ng/mL recombinant human TGF-b1 (R&D) or buffer (5% BSA-HCl), Smad 3 phosphorylation inhibitor SIS3 (EMD Millipore) at 10 mM, or the p38 MAPKa inhibitor SB202190 (Tocris) at 10 mM for 24 h under normal culture conditions.
Quantitative real-time PCR
To measure changes in gene expression, mRNA reverse transcription was carried out using the qScript cDNA synthesis kit (Quanta, VWR) per manufacturer's instructions. Briefly, cells were harvested with trypsin after 24 h in culture and total RNA was extracted using the RNeasy Mini Kit (Qiagen). The qScript cDNA supermix was used to synthesize cDNA using 1 mg total RNA. The expression of PTHrP, Gli2, Ib3 and TGF-b RII was measured in triplicate by quantitative qRT-PCR using validated TaqMan primers with the 7500 Real-Time PCR System (Applied Biosciences) using the following cycling conditions: 95 C for 15 s and 60 C for 1 min, preceded by an initial incubation period of 95 C for 10 min. Quantification was performed using the absolute quantitative for human cells method using 18S as an internal control.
Western blot analysis
Cells were harvested 24 h after seeding on PUR substrates in a radioimmunoprecipitation buffer containing a cocktail of protease and phosphatase inhibitors (Pierce). Equal protein concentrations were prepared for loading with NuPAGE sample buffer (Life Technologies) and separated on a 10% SDS-PAGE gel (BioRad). Proteins were transferred to a PVDF membrane and blocked with 5% BSA in TBS containing 0.1% Tween-20 for 1h at room temperature, followed by incubation with either phospho-p38MAPK (1:1000, Cell Signalling), p38MAPK (1:1000, Cell Signalling), phospho-Smad2/3 (1:1000, Cell Signalling) or Smad2/3 (1:1000, Cell Signalling) antibodies overnight at 4 C. After washing, membranes were blotted with anti-rabbit IgG (1:2000, SantaCruz), and bands were detected by enhanced chemiluminescence using an In-Vivo MS FX Pro (Bruker). Membranes were then stripped and reprobed using an antibody for b-actin (1:5000, Sigma) as a loading control. Phosphorylated events were quantified by normalizing the band intensity of phosphorylated protein to total protein. Analysis was performed using Image J software.
F€ orster resonance energy transfer (FRET) microscopy
To investigate the association of TGF-b RII and Ib3, we performed F€ orster Resonance Energy Transfer (FRET) and confocal microscopy. Briefly, the donor antibody (anti Ib3 (SantaCruz)) was labeled with Alexa Fluor ® 488 Carboxylic Acid, Succinimidyl Ester 
Immunoprecipitation
To investigate association of membrane proteins, cells were lysed using a 1% Nonidet-P40 buffer containing a cocktail of protease and phosphatase inhibitors (Pierce). 400 mg total protein lysate per tube was incubated overnight at 4 C under gentle endover-end mixing with anti-TGF-bRII (1 mg, Santa Cruz). Subsequently, the immune complex was captured with protein A/G agarose resin, thoroughly washed with lysis buffer and eluted with non-reducing sample buffer. Proteins were then separated on a 10% SDS-PAGE gel (BioRad) and transferred to a PVDF membrane. Following blocking with 5% milk in TBS with 0.1% Tween-20, membranes were incubated with anti-Ib3 (Santa Cruz, 1:1000) or anti-TGF-b RII (Santa Cruz, 1:1000) at 4 C overnight. After washing, membranes were blotted with anti-rabbit or anti-mouse IgG (1:5000 Santa Cruz), and bands were detected by enhanced chemiluminescence using an In Vivo MS FX Pro (Bruker). The Ib3 and TGF-bRII co-precipitation was quantified by normalizing the band intensity of Ib3 pulled down with TGF-bRII to total protein (anti-TGF-bRII). Analysis was performed using Image J software.
Immunofluorescent staining
MDA-MB-231-GFP cells were grown on rigid or compliant PUR films for 24 h. Cells were fixed in 10% Formaldehyde and blocked in 3% BSA for 1 h. Fixed cells were labeled with an anti-Focal Adhesion Kinase antibody (FAK, 1:800, Cell Signaling) overnight at 4 C. An Alexa Fluor ® 546-tagged secondary antibody was used for detection of FAK. Images were obtained at 40x and 100x on an Olympus BX41 upright microscope. Cell area and FAK area were measured by ROI measurements using Metamorph Image analysis software.
Animal study
MDA-MB-231 cells stably transfected with either a shb3 or shControl plasmid (SantaCruz) were injected into the tibia of 4e6 week old athymic nude mice (Harlan). Tumor progression was monitored by weekly x-ray imaging on a XR-60 digital radiography system (Faxitron) at 35kVp for 8 s. Mice were sacrificed at 25 days post tumor cell inoculation and hindlimbs were harvested for ex vivo analysis. Bone volume was assessed by micro-computed tomography analysis using a Scanco mCT 40 (Scanco Medical) at 70kVp and 125 mA with a 12 mm voxel size and an integration time of 300ms. Histomorphological analysis was performed on 4 mm thick decalcified, paraffin-embedded sections. Hematoxylin and Eosin staining was used to evaluate tumor burden. All animal studies were performed in compliance with the Vanderbilt University Institutional Animal Care and Use Committee and the National Institutes of Health guidelines.
Statistical analysis
All statistical analyses were performed using InStat version 3.03 software (GraphPad Software, Inc.). Values are presented as mean ± SEM, and P values determined using unpaired t test, where *, P < 0.05.
Results
PTHrP, Gli2 and Ib3 expression correlate with rigidity
PUR films coated with fibronectin (Fn) were utilized to analyze the gene expression of MDA-MB-231-bone (bone metastatic clone of the original breast tumor line), RWGT2 (bone metastatic lung) [28] , and PC3 (bone metastatic prostate) cancer cells as a function of matrix rigidity. All cell lines are prone to metastatic invasion of bone and the consequent formation of osteolytic tumors. MDA-MB-231, RWGT2, and PC3 cells expressed significantly increasing (p < 0.001) amounts of PTHrP, Gli2, and Ib3 as the substrate rigidity increased from basement membrane levels (2000e70,000 kPa) to that of trabecular bone (90,000e365,000 kPa) (Fig. 2AeC) . Gli2 protein expression also significantly increased (see Fig. 1A in Ref. [32] ). Furthermore, when imaged by scanning electron microscopy (SEM), MDA-MB-231 and RWGT2 cells showed a spread phenotype on the rigid substrate, while cells grown on the compliant substrates were smaller and less spread (Fig. 2D) . While integrin expression correlates with rigidity in breast tumors in mice [33] , the modulus of the mammary fat pad in these previous studies was <1.5 kPa, which is 10,000 times less rigid than the PUR substrates shown in Fig. 1 . Interestingly, the expression of Ib1 and Ib5 in MDA-MB-231 cells does not change significantly with increasing substrate rigidity, indicating that the cells are interacting with the matrix primarily through Ib3 (see Fig. 1BeD in Ref. [32] ). To confirm that changes in Ib3 concentration were mediated by rigidity and not differences in fibronectin (Fn) surface concentration, Fn was adsorbed on PUR films prior to culture of MDA-MB-231 cells. We have previously reported that Fn surface concentration is a function of Fn solution concentration but relatively independent of the rigidity of the PUR film [16] . Thus, we treated rigid and compliant films with varying concentrations (0e50 mg/ml) of Fn to vary the surface concentration (Fig. 2E) . (Fig. 2E) . However, as expected there was a significant change in Ib3 between cells grown on rigid and compliant films. Furthermore, when tumor cells were cultured on PUR films treated with other matrix proteins, such as vitronectin, type I collagen, or poly-L-lysine, there was no change in the gene expression of Ib3, PTHrP, and Gli2 as a function of rigidity (see Fig. 2 in Ref. [32] ). These observations suggest that a threshold concentration of Fn, a primary binding ligand for a v b 3 , is required to activate integrinmediated changes in gene expression in response to matrix rigidity.
To determine whether or not these integrin-mediated changes in gene expression at moduli >1.5 kPa were a result of traction forces, we looked downstream of the mechanotransduction pathway at how focal adhesion kinase (FAK) and cell area change in response to rigidity. Immunofluorescent images of MDA-MB-231-GFP cells labeled with anti-Focal Adhesion Kinase (FAK) (Fig. 2FeG ) reveal increases in cell size and FAK area with respect to substrate rigidity. Additionally, a linear relationship is observed between FAK area and cell area with increasing modulus (Fig. 2H) . These results signify that the tumor cells can respond to mechanical stimuli at rigidities ranging from basement membrane to that of trabecular bone.
Ib3 mediates expression of PTHrP and Gli2 by tumor cells
The effect of Ib3 expression on PTHrP and Gli2 was investigated utilizing MDA-MB-231 cells. In one treatment group, cells were transfected with shRNA inhibiting Ib3 (shb3 cells). MDA-MB-231 cells were also treated with an inhibitor of a v b 3 integrin (LM609 [34] ) or an RGD-mimicking peptide (Cilegnitide [35] ). All three methods of blocking integrin function or expression produced a significant decrease (p < 0.01) in PTHrP mRNA (Fig. 3AeC) and Gli2 mRNA (Fig. 3DeF) , as well as Gli2 protein (see Fig. 3AeC in Ref. [32] ) compared to control groups, indicating that Ib3 mediates Gli2 and PTHrP expression in MDA-MB-231-bone cells. Furthermore, when RWGT2 and PC3 cells were treated with LM609 or Cilengitide, PTHrP and Gli2 mRNA expression significantly decreased (see Fig. 3DeG in Ref. [32] 
Expression of PTHrP and Gli2 is mediated by integrin/matrix binding and activation of Src family kinases
To further analyze the effects of Ib3 expression on PTHrP and Gli2 expression, MDA-MB-231 cells were transfected to either overexpress Ib3 (OE b3 cells) or silence Ib3 (shb3). OE b3 cells were shown to have increased PTHrP expression compared to mocktransfected control cells (see Fig. 4A in Ref. [32] ). Additionally, when cultured on rigid and compliant PUR films, the OE b3 cells showed no statistical difference in PTHrP gene expression (see Fig. 4B in Ref. [32] ). While shb3 cells had significantly decreased PTHrP and Gli2 (Fig. 3A,D) , there was no significant changes observed in a panel of genes important in tumor metastasis (see Fig. 7B in Ref. [32] ). Thus, the OE b3 and shb3 cells were utilized as model cell systems with high and low integrin expression, respectively (see Fig. 4CeD in Ref. [32] ). When cultured on rigid and compliant PUR films and imaged with scanning electron microscopy, the OE b3 cells were larger and more spread than the shb3 cells on both rigid and compliant substrates (Fig. 4A) . Binding of integrin a v b 3 to Fn activates Src family kinases, an early event which leads to bridging of integrins to the cytoskeleton, tensioning of the integrin-matrix catch bond, and consequent displacement events [20, 21] . To investigate the relative contributions of integrin/matrix binding and displacement events to rigidity-mediated changes in gene expression, OE b3 cells were treated with inhibitors of myosin II and ROCK, which are key regulators of cell contractility. MDA-MB-231 and OE b3 cells were treated with blebbistatin, a drug that blocks the myosin heads in a complex with low actin-binding affinity [36] . Treatment of OE b3 cells with blebbistatin did not change PTHrP, Gli2, or Ib3 gene expression, but treatment of MDA-MB-231 cells with blebbistatin decreased PTHrP, Gli2 and Ib3 expression (p < 0.05, Fig. 4BeD ). Interestingly, myosin inhibition with blebbistatin did not change FAK area in MDA-MB-231 cells or OEb3 cells (Fig. 4HeI) In a related experiment, shb3 cells were treated with bombesin, a Src stimulator that upon integrin activation induces bridging of integrins to the cytoskeleton through talin [21] as well as tyrosine phosphorylation of TGF-b RII [26] . Treatment with bombesin significantly increased PTHrP, Gli2, and Ib3 gene expression in MDA-MB-231 and shb3 cells (p < 0.005, Fig. 4EeG ). Taken together, these observations suggest that integrin activation regulates Gli2 and PTHrP expression through Src-mediated phosphorylation of TGF-b RII.
Physical interactions between Ib3 and TGF-b receptor II (TGF-b RII) correlate with rigidity
During epithelial-mesenchymal transition (EMT), Ib3 physically interacts with TGF-b RII followed by phosphorylation of TGF-b RII by Src [26] . However, EMT typically occurs at the primary site, where the matrix is 10,000-fold more compliant than the bone microenvironment. To test the hypothesis that interactions between TGF-b RII and Ib3 correlate with rigidity, we probed the interactions between these plasma membrane proteins by F€ orster resonance energy transfer (FRET) analysis (Fig. 5A) . MDA-MB-231, RWGT2, or PC3 cells were incubated with antibodies for Ib3 and TGF-b RII that were labeled with a fluorescent FRET pair (Alexa Fluor 488 and Alexa Fluor 546). The fluorescent signal from IgG control antibodies labeled with the same FRET pair was subtracted from the signal for the Ib3 and TGF-b RII antibodies to calculate the background-subtracted FRET response. MDA-MB-231, RWGT2, and PC3 cells induced a greater FRET response when cultured on substrates with bone-like rigidity than on compliant substrates (p < 0.05, Fig. 5F ). Representative confocal images show colocalization and an FRET response of Ib3 and TGF-b RII in the cell membrane (Fig. 5BeE) . Interestingly, TGF-b RII was not affected by rigidity, which is supported by our qRT-PCR results (see Fig. 5A in Ref. [32] [cite DIB]). These results were confirmed by immunoprecipitation for TGF-b RII, which demonstrated increased coprecipitation of TGF-b RII and Ib3 on rigid compared to compliant substrates (Fig. 5G) . To ensure that the Fn coating was not affecting the expression of either FRET target, a dose-response analysis was conducted (see Fig. 5B in Ref. [32] ). The FRET signal did not increase appreciably on rigid substrates above the threshold concentration of 0.5 mg/mL. Thus Ib3, which is expressed significantly more on substrates with bone-like rigidity, physically interacts with TGF-b RII on rigid substrates, resulting in elevated osteolytic gene expression.
Exogenous TGF-b stimulation of PTHrP and Gli2 is Ib3-dependent
To investigate crosstalk between TGF-b signaling, which stimulates expression of PTHrP and Gli2 [14] , and Ib3emediated signaling, shb3-transfected or LM609-treated MDA-MB-231 cells were cultured in serum-free media on rigid PUR films and treated with exogenous TGF-b. shb3 cells showed significantly reduced PTHrP and Gli2 (p < 0.01, Fig. 6AeB ) mRNA expression even in the presence of exogenous TGF-b. Inhibition of Ib3 with LM609 showed similar results in MDA-MB-231 bone (p < 0.01, Fig. 6CeD ) and RWGT2 and PC3 cells (see Fig. 6 in Ref. [32] ). However, Ib3 expression was not affected by TGF-b stimulation (Fig. 6E) . Thus, both TGF-b and Ib3 signaling are required for Gli2 and PTHrP expression. Since TGF-b signaling in bone metastases can be mediated through Smad-or p38 MAPKa-dependent downstream signaling [37] , we investigated whether one or both of these pathways is stimulated by interactions between Ib3 and TGF-b RII in the presence of exogenous TGF-b. Western blot analysis revealed significant changes in expression and phosphorylation of p38 MAPKa (Fig. 7A) , but no significant difference in expression and phosphorylation of SMAD2/3 (Fig. 7B) when MDA-MB-231 cells were cultured on rigid compared to compliant substrates. Inhibition of p38 MAPKa via SB202190 significantly decreased PTHrP and Gli2 expression by quantitative qRT-PCR on rigid substrates (p < 0.05), while the Smad inhibitor SIS3 significantly decreased PTHrP (p < 0.05) but not Gli2 expression on rigid substrates (Fig. 7CeD) . These observations suggest that physical interactions between Ib3 and TGF-b RII in response to bone rigidity activate TGF-b signaling primarily through p38 MAPKa.
Inhibition of Ib3 in MDA-MB-231 cells reduces bone destruction in vivo
Since inhibition of Ib3 with shRNA reduced the expression of factors associated with bone destruction in vitro, we reasoned that inhibiting Ib3 would slow the progression of tumor-induced bone disease in vivo. Considering that blocking Ib3 reduces metastasis [38] , we chose to directly inject mice with MDA-MB-231 cells stably expressing shb3 into the tibia to eliminate any potential effect on metastasis. Ex vivo analyses using mCT (Fig. 8A, C) and radiography (Fig. 8G ) demonstrated a reduction in bone resorption, as evidenced by increased BV/TV (Fig. 8E ) and reduced lesion number (Fig. 8G ) for shb3 cells compared to mock-transfected cells. Blocking Ib3 did not have a significant effect on tumor growth (Fig. 8B, D , and F and see Fig. 7 in Ref. [32] ), but the control cells grew in the trabecular bone closest to the injection site, while the shb 3 cells resulted in tumors in the marrow space. Previous studies have shown that blocking tumor-produced Ib3 reduces metastasis [38] and that systemic delivery of the Ib3 inhibitor Cilegnitide inhibits bone resorption in a mouse model of bone metastasis [35] . While these previous studies highlight the role of Ib3 in bone metastasis, they do not address the question of how tumor cells become established in the bone microenvironment. The reduced bone resorption and dispersion of tumor cells in the marrow space associated with shb3 cells points to a major role of tumor-produced Ib3 in switching tumor cells from the pre-osteolytic to the osteolytic phase in the bone microenvironment.
Discussion
In soft tissue, the increase in the rigidity of the extracellular matrix surrounding the tumor activates integrins, which increases both mitogenic signaling through soluble factors and also tumor cell contractility through Rho/ROCK [39, 40] . Increased cell contractility further increases matrix rigidity, which drives a positive feedback loop that triggers malignant transformation in epithelial cells [39, 41] and in some cases TGF-b-dependent EMT [42] . However, the extracellular matrix in bone is several orders of magnitude stiffer than soft tissue and cannot be directly remodeled by tumor cells [43] . Thus, the previously observed increase in Gli2 and PTHrP expression when metastatic tumor cells were cultured on substrates with bone-like rigidities [16] cannot be explained by this mechanical positive feedback loop associated with malignant transformation in soft tissue [39, 40] . In this study, we utilized 2D polymeric substrates with rigidities tunable from that of the basement membrane to cortical bone to investigate the mechanism by which matrix rigidity regulates gene expression in tumor cells that are metastatic to bone. On matrices with rigidity equal to or exceeding that of trabecular bone, both expression of Ib3 as well as its co-localization with TGF-b RII increased, resulting in upregulation of TGF-b signaling through p38MAPK and Smad 2/3 and consequent Gli2 and PTHrP expression (Fig. 9) .
Previous studies of our own and others have reported that metastasis to bone [44] and increased PTHrP expression in response to matrix rigidity [16] are mediated by ROCK, which stimulates contractility through the substrate-Fn-avb3-actin-myosin II mechanically sensitive cassette [20, 39] . Consistent with these observations, blebbistatin significantly reduced contractility, Ib3, Gli2 and PTHrP expression in MDA-MB-231 cells but not in OEb3 cells (Fig. 4) . Thus, it was not possible to de-couple the effects of Ib3 expression and contractility, which represents a limitation of this study. Both Ib3 expression and FAK area increased with rigidity on substrates stiffer than 10 MPa, which suggests that the contractile forces exerted by the cells increase over the MPa range. Current evidence suggests that contractility-mediated mechanosensory events are driven by uniform displacements (100e150 nm) of the matrix [21e23]. Values ranging from 10 to 100 kPa have been proposed as the upper limit of matrix rigidity that can result in a displacement of 100e150 nm [21, 24] . On substrates >100 kPa, cells have been suggested to be in a state of isometric contraction in which they cannot respond to further changes in rigidity. Consequently, the observed increase in Gli2 and PTHrP expression by tumor cells interacting with bone-like matrices stiffer than 10 MPa cannot be explained by the rigidity sensing cycle based on uniform displacements of the matrix. While previous studies have identified the mechanosensory role of Ib3 for cells cultured on polyacrylamide hydrogels (<1 MPa) [23, 45, 46] our observations point to a role for tumor-produced Ib3 in the regulation of bone metastatic genes in response to rigid matrices that cannot be displaced > 100 nm by cells. To our knowledge, the present study is the first to show that rigid substrates can alter soluble factor signaling through physical interactions between integrins and growth factor receptors.
Force-generating events that drive matrix displacement in the rigidity-sensing cycle occur downstream of integrin/matrix binding and consequent Src activation [21] . In the present study, in vitro analyses demonstrated that the increase in Ib3 on rigid matrices resulted in greater co-localization with TGF-bRII up-stream of Src. Integrins have been reported to couple with growth factor receptors such as TGF-bRII [26] and HER2 [47] , resulting in the activation of downstream signaling cascades through Src phosphorylation of downstream targets. In the present study, activation of Src in shb3 cells by treatment with bombesin rescued the expression of Ib3, Gli2, and PTHrP. This observation is consistent with previous studies reporting that Src activates phosphorylation of TGF-b RII after formation of the Integrin b3-TGF-b RII complex [26, 48] . control cells (AeB) and Ib3 knockdown cells (CeD) significantly decreased bone destruction, which is mirrored in the quantified bone volumes (E). Histological analysis showed that the tumor is present in both control and shb3 cells (F); however, the tumor is shifted to the marrow and there is little bone destruction in the shb3 cells (EeG). Quantified histomorphometry shows no significant difference in tumor burden between control and shb3 cells (F). Additionally, quantification of lesion numbers from x-ray scans (G) show a reduced number of osteolytic lesions in the animals implanted with shb3 cells (*p < 0.05).
Ib3 has been associated with cancer-induced bone disease through its essential role in osteoclast function [49, 50] and metastasis to bone [38] . Here we show that Ib3 expression directly regulates tumor cell gene expression, and that inhibiting Ib3 in tumor cells blocks bone destruction by reducing the expression of tumor-derived factors like PTHrP. This suggests that integrin inhibitors could block establishment of tumors in bone by inhibiting both osteoclast activity and also the expression of tumor-derived factors. Two a v b 3 integrin inhibitors are currently in clinical trials for treatment of different cancers [51] . Cilengitide, a cyclic peptide that inhibits integrin signaling, has been evaluated in a Phase III clinical trial for glioblastoma, but ultimately did not alter glioblastoma progression [52, 53] . Alternatively, Etaracizumab, an a v b 3 integrin antibody, has shown promise in pre-clinical trials for metastatic melanoma and castration-resistant prostate cancer and is now in Phase II clinical trials [51] . Our data suggest that these inhibitors may be effective for blocking metastatic tumors from responding to the rigid bone matrix and secreting factors (like PTHrP) associated with their transition to the osteolytic phase. Coupled with their previously reported anti-angiogenic, anti-metastatic, and anti-osteoclast properties, integrin inhibition is a promising target for drug development. Importantly, our data indicate that integrin inhibition (Cilingitide and LM609) reduces gene expression in multiple tumor types, suggesting that it may be broadly applicable for inhibiting metastatic disease. Additionally, our data suggest that TGF-b inhibitors, which are also in clinical trials for use in cancer, may have similar effects at inhibiting the ability of the tumor to respond to the rigid mineralized bone matrix [54] , and may in part explain positive pre-clinical results from using TGF-b inhibitors in bone metastatic disease [55, 56] .
The metastasis seed pre-selection mechanism postulates that the breast stroma contributes to the selection of breast cancer cells conditioned for metastasis to bone [10] . However, once tumor cells become established in bone, the factors mediating their transition from the pre-osteolytic to the osteolytic phase have not been elucidated [11] . In this study, we have shown that rigid, bone-like matrices stimulate expression of osteolytic factors in vitro through Ib3 and TGF-b RII complexation, which activates p38MAPKa signaling (and partially Smad 2/3) through Src phosphorylation [26] . This subsequently induces expression of the osteoclastogenic factor PTHrP and its transcription factor Gli2. Taken together, these data significantly add to our understanding of how tumor cells respond to the rigid mineralized bone matrix, and may have broad implications for other tumor types that grow in bone and for non-tumor cells present in the bone. Understanding the mechanisms involved in the establishment of these metastases could ultimately lead to new targeted therapies to improve clinical outcomes. Furthermore, this study suggests that Ib3 inhibitors, which are currently in clinical trials for several tumor types, may also inhibit tumor-induced bone disease.
Conclusion
Our results demonstrate the importance of the physical rigidity of the tumor microenvironment in the regulation of genes important in mediating bone destruction, such as PTHrP and Gli2. This regulation was mediated by physical interactions between Ib3 and TGF-bRII, which induced MAPK and Smad-mediated signaling. These data suggest that the response to rigidity may influence bone metastatic tumor cells to transition from a quiescent state to a bone destructive state, therefore blocking the cell's ability to sense this rigidity presents a novel therapeutic opportunity. Importantly, Ib3 inhibitors are currently used clinically for other diseases and may be a promising approach for preventing the progression of tumors residing in bone.
